Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 3-10 , February 2000

Radioimmunodiagnosis and therapy

  • M.J. Verhaar-Langereis

      Affiliations

    • Department of Internal Medicine/Oncology, University Medical Centre Utrecht, The Netherlands
    • ,
  • B.A. Zonnenberg

      Affiliations

    • Department of Internal Medicine/Oncology, University Medical Centre Utrecht, The Netherlands
    • ,
  • J.M.H. de Klerk

      Affiliations

    • Department of Nuclear Medicine, University Medical Centre Utrecht, The Netherlands
    • ,
  • G.H. Blijham

      Affiliations

    • Department of Internal Medicine/Oncology, University Medical Centre Utrecht, The Netherlands

References 

    REFERENCES
  1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497
  2. Epenetos AA, Mather S, Granowska M. Targeting of I-123 labelled tumour associated monoclonal antibodies to ovarian, breast and gastro-intestinal tumours. Lancet. 1982;6:999–1004
  3. Anderson WI, Strand M. Radiolabelled antibody: iodine versus radiometal chelates. NCI monogr. 1987;3:149–151
  4. DeNardo SJ, DeNardo GL, O’Grady LF. Pilot studies of radioimmunotherapy of B cell lymphoma and leukaemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconjugates Radiopharmaceut. 1988;1:17
  5. Vitetta ES, Stone M, Amlot P. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991;51:4052–4058
  6. Pai LH, Batra JK, Fitzgerald DJ. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxins. Proc Natl Acad Sci USA. 1991;88:3358–3362
  7. Goldenberg DM, Kim EE, Bennet SJ. Carcinoembryonic antigen radioimmunodetection in the evaluation of colorectal cancer and in the detection of occult neoplasms. Gastroenterology. 1983;84:524–532
  8. Riethmuller G, Schneider-Gadicke E, Schlimok G. Randomised trial of monoclonal antibody antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet. 1994;343:1177–1183
  9. Riethmuller G, Holz E, Schlimok G. Monoclonal antibody therapy for resected Dukes C colorectal Cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788–1794
  10. Miller RA, Maloney DG, Warnke R. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517–522
  11. Press OW, Eary JF, Badger CC. Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027–1038
  12. Kaminski MS, Zasadny KR, Francis IR. Radioimmunotherapy of B-cell lymphoma with (131I) anti-B1 (anti CD-20) antibody. N Engl J Med. 1993;329:459–465
  13. DeNardo SJ, DeNardo GL, Kukis DL. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation, dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med. 1999;40:302–310
  14. Knox SJ. Radioimmunotherapy of the non-Hodgkins lymphoma’s. Sem.Radiat. Oncol. 1995;5:331–334
  15. Juweid M, Swayne LC, Sharkey RM. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131 labeled murine and humanized MN-14 anticarcinoembryonic antigen monoclonal antibodies. Gynecol-Oncol. 1997;67(3):259–271
  16. Amlot PL, Stone MJ, Cunningham D. A phase I study of an anti-CD-22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993;82:2624–2633
  17. Bagshaw KD, Sharma SK, Springer CJ. Antibody directed prodrug therapy: a pilot-scale clinical trial. Tumor Targeting. 1995;1:17–29
  18. Baxter LT, Zhu H, Mackensen DG. Biodistribution of monoclonal antibodies: Scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55:4522–4611
  19. Mach JP, Carrell SE, Forni M. Tumor localization of radiolabelled antibodies against carcinoembryonic antigen in patients with carcinoma. N Engl J Med. 1980;303:5–10
  20. Esteban JM, Colcher D, Sugarbaker P. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered Mab B72.3. Int. J. Cancer. 1987;39:50–59
  21. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50:814S–819S
  22. Carrasquillo JA, Abrams PG, Schroff RW. Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. J Nucl Med. 1988;29:39–47
  23. Pimm MV, Perkins AC, Armitage NC. The characterisitics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localisation of radiolabelled monoclonal antibody in cancer patients. J Nucl Med. 1985;26:1011–1023
  24. Rosen ST, Zimmer AM, Goldman-Leikin R. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphoma using a 131I labelled monoclonal antibody: An Illinois Cancer Council Study. J Clin Oncol. 1987;5:562–573
  25. Meredith RF, Khazaeli MB, Liu T. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med. 1992;33:1648–1653
  26. DeNardo SJ, DeNardo GL, Lamborn KR. Enhancement of tumor uptake of monoclonal antibody in nude mice with PEG-I1–2. Antib Immunoconjug Radiopharm. 1991;4:859–870
  27. Baxter LT, Jain RK, Svensio E. Vascular permeability and interstitial diffusion of macromolecules in the hamster cheek pouch: effects of vasoactive drugs. Microvasc Res. 1987;34:336–348
  28. Denardo GI, Kukis DL, Denardo SJ. Enhancement of 67Cu-2IT-BAT-Lym-I therapy in mice with human Burkitt’s lymphoma using I1–2. Cancer. 1997;80(12suppl):2576–2582
  29. Hornick JL, Khawli LA, Sharif J. Pretreatment with a monoclonal antibody/IL-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumours. Clin Cancer Res. 1999;5(1):51–60
  30. King DJ, Mountain A, Adair JR. Tumor localization of engineered antibody fragments. Antibody, immunoconjugates, and radiopharmaceuticals. 1992;5:159–170
  31. Colcher D, Bird R, Roselli M. In vivo tumor targeting of a recombinant single-chain antigen binding protein. J Nalt Cancer Inst. 1990;79:1393–1401
  32. Yokota T, Milenic DE, Whitlow M. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402–3408
  33. Yokota T, Milenic DE, Whitlow M. Microaudiographic analysis of the normal organ distribution of radionated single-chain Fv and other immunoglobulin forms. Cancer Res. 1993;53:3776–3783
  34. Bird RE, Hardman KD, Jacobson JW. Single-chain antigen binding proteins. Science. 1988;242:423–426
  35. Milenic DE, Yokota T, Filpula DR. Construction, binding properties, metabolism, and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991;51:6363–6371
  36. Williams WV, Moss DA, Kieber-Emmons T. Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci USA. 1989;86:5537–5541
  37. Chester KA, Begent RH, Robson L. A new way to generate clinically useful antibodies. Lancet. 1994;343:55
  38. Reilly RM. Radioimmunotherapy of malignancies. Clin Pharm. 1991;10:359–375
  39. Begent RHJ, Ledermann JA, Green A. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer. Br J Cancer. 1989;60:406–412
  40. Marshall D, Pedley RB, Boden JA. Clearance of circulating radio-isotopes using streptavidin or second antibodies in a xenograft model. Br J Cancer. 1994;69(3):502–507
  41. Blumenthal RD, Sharkey RM, Snyder D. Reduction by anti-antibody administration of the radiotoxicity associated with131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. J Natl Cancer Inst. 1989;81:19–49
  42. Malamitsij J, Skarlos D, Fotiou S. Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. J Nucl Med. 1988;29:1910–1915
  43. Epenetos AA. Antibody-guided irradiation of malignant lesions; Three cases illustrating a new method of treatment. Lancet. 1984;11:1441–1443
  44. Schlom J, Horan Hand P, Greiner JW. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res (suppl). 1990;50:820s–827s
  45. Begent RHJ, Verhaar MJ, Chester KA. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Med. 1996;2(9):979–984
  46. Larson SM, El-Shirbiny AM, Divgi CR. Single chain antigen binding protein (sFv CC49). First human studies in colorectal metastatic to liver. Cancer. 1997;80:2458–2468
  47. Schlom J, Eggensperger D, Colcher D. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res. 1992;52:1067–1072
  48. Velders MP, Litvinov SV, Warnaar SO. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res. 1994;54:1753–1759
  49. Pullyblank AM, Monson RT. Monoclonal antibody treatment of colorectal cancer. Br J Surgery. 1997;84:1511–1517
  50. Osbourne JK, Field A, Wilton J. Generation of a panel of related scFv antibodies with high affinities for human CEA. Immunotechnology. 1996;2(3):181–196
  51. Behr TM, Sharkey RM, Juweid ME. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med. 1997;38(3):409–418
  52. Begent RHJ, Chester KA. Single-chain Fv antibodies for targeting cancer therapy. Biochem Soc Trans. 1997;25(2):715–717
  53. Thomas GD, Chappell MJ, Dykes PW. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 1989;49:3290–3296
  54. Weiner LM, Holmes M, Adams GP. A human tumor xenograft model of therapy with abispecific monoclonal antibody targeting c-erB-2 and CD16. Cancer Res. 1993;53:94–100
  55. Gautherot E, Bouhou J, Le-Doussal JM. Therapy for colon carcinoma xenografts with bispecific antibody-targeted iodine-131-labeled bivalent hapten. Cancer. 1997;80(12):2618–2623
  56. Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maruel C. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med. 1999;40:198–204
  57. Guadagni F, Witt PL, Robbins PF. Regulation of carcinoembryonic antigen expression in different human colorectal tumour cells by interferon-gamma. Cancer Res. 1990;50:6248–6255
  58. Wilder RB, Langmuir VK, Medonca HL. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Cancer Res. 1993;53:3022–3027
  59. Greiner JW, Guadagni F, Horan Hand P. Augmentation of tumor antigen expression by recombinant human IFNs: enhanced targeting of monoclonal antibodies to carcinomas. In:  Goldenberg DM editors. Cancer imaging with radiolabelled antibodies. MA, Nijhoff: Norwell; 1990;p. 413–432
  60. Roselli M, Guadagni F, Buonomo A. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma- associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J. Clin. Oncol. 1996;14(7):2031–2042
  61. Dansky Ullmann C, Salgaller M, Adams S. Synergistic effects of I1–6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells; role for endogenous IFN-beta. Cytokine. 1995;7(2):118–129
  62. Dorudi A, Northover JMA, Vile RG. Gene transfer therapy in cancer. Br J Surgery. 1993;80:566–572
  63. Raben D, Buchsbaum DJ, Khazaeli MB. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene therapy. 1996;3:567–580
  64. Ledermann JA, Begent RHJ, Bagshawe KD. Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A. Br J Cancer. 1988;58:654–657
  65. Courtenay-Luck NS, Epenetos AA, Moore R. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986;46:6489–6493
  66. Wilder RB, DeNardo GL, DeNardo SL. Radioimmunotherapy: Recent results and future directions. J Clin Oncol. 1996;14(4):1383–1400
  67. Kuus-Rachel K, Graver LS, Korawvodin LM. Will immunogenicity limit the use, efficacy and future development of therapeutic monoclonal antibodies. Clinical and Diagnostic laboratory immunology. 1994;1(4):365–372
  68. Kosmas C, Epenetos AA, Courtenay-Luck NS. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells, that proliferate in vitro in response to the antibodies as antigen. Br J Cancer. 1991;64:494–500
  69. Schultes BC, Yang R, Agopsowicz K. Anti-idiotype induction therapy for ovarian cancer: immune responses in patients injected with Ovarex ™ Mab-B43.13. Proc ASCO. 1999;1399
  70. Ledermann JA, Begent RHJ, Massof C. A phase 1 study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer. 1990;47:659–664
  71. Begent RHJ, Ledermann JA, Bagshawe KD. Dosimetry and immunogenicity of radioimmunotherapy with chimeric B72.3 antibody in colorectal cancer. Advances in the applications of monoclonal antibodies in Clinical Oncology. 1991;57
  72. Hale G, Clark MR, Marcus R. Remission induction in non-Hodgkin’s lymphoma with reshaped human monoclonal antibody CAMPATH-1. Lancet. 1988;11:1394–1399
  73. Hird V, Verhoeyen M, Badley RA. Tumour localisation with a radioactivity labelled reshaped human monoclonal antibody. Br J cancer. 1991;64:911–914
  74. Huston JS, George AJT, Adams GP. Single-chain Fv radioimmunotargeting. The Quartely J Nucl Med. 1996;40(3):320–333
  75. Karmochkine M, Bussel A, Leon A. Long term plasma exchange. Analysis of indications, outcome and side effects. Annales de Medicine Interne. 1993;145(5):373–375
  76. Verhaar MJ, Chester KA, Keep PA. A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma. Int J Cancer. 1995;61:497–501
  77. Clackson T, Hoogenboom HR, Griffiths AD. Making antibody fragments using phage display libraries. Nature. 1991;352:624–628
  78. Verhaar MJ, Keep PA, Hawkins RE. 99 mTc radiolabelling using a phage-derived single chain Fv with a C-terminal cysteine for colorectal tumour imaging. J. Nucl. Med. 1996;37(5):868–872
  79. Turner DJ, Ritter MA and George AJT. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J Immunol Methods. 1997;205:43–54
  80. Whitlow M, Bell BA, Feng SL. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng. 1993;6:989
  81. Pietersz GA, Patrick MR, Chester KA. Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99 m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody. J Nucl Med. 1998;39(1):47–56
  82. McCartney JE, Tai MS, Oppermann H. Refolding of a single-chain Fv with cterminal cysteine (scFv): Formation of disulfide bonded homodimers of anti-c-erbB-2 and anti-digoxin sFv. Miami Short Reports. 1993;3:91
  83. Michael NP, Chester KA, Melton RG. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2: anti-CEA scFv fusion protein. Immunotechnology. 1996;2(1):47–57
  84. Eldin P, Pauza ME, Hieda Y. high-level secretion of two antibody single chain Fv fragments by Pichia pastoris. J Immunol Methods. 1997;201:67–75
  85. Nourigat C, Badger CC, Bernstein ID. Treatment of lymphoma with radiolabelled antibody; Elimination of tumor cells laking target antigen. J Natl Cancer. 1990;82:47–50
  86. Zalutsky MR, Gard PK, Friedman HS. Labeling monclonal antibodies and F(ab’)2 fargments with the alpha-particle emitting nuclide astatine-211. Preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA. 1989;86:7149–7153
  87. Daghighian F, Pentlow KS, Larson SM. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: Positron emission tomography studies of iodine-125 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med. 1993;20:402–409
  88. Beekman FJ, Kamphuis C, Viergever MA. Improved SPECT quantitation using fully three-dimensional iterative spatially variant response compensation. IEEE Trans on Med Imaging. 1996;15:491–499
  89. Covell DG, Barbet J, Holton OD. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2and Fab’ in mice. Cancer Res. 1986;46:3969–3978
  90. Howell RW, Rao DV, Sastry KSR. Macroscopic dosimetry for radioimmunotherapy: non-uniform activity distributions in solid tumors. Med Phys. 1989;16:66–74
  91. Sharkey RM, Blumenthal RD, Behr TM. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer. 1997;72:477–485
  92. Rao DV, Howell RW. Time-dose fractionation in radioimmunotherapy: implications for selecting radionuclides. J. Nucl. Med. 1993;34:1801–1810
  93. Moi MK, DeNardo SJ, Meares CF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res. 1990;50:789s–793s
  94. Kosmas C, Snook DE, Gooden CS. Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunconjugates for imaging and therapy. Cancer Res. 1992;52:904–911
  95. Stewart JSW, Hird V, Snook D. Intraperitoneal Yttrium-90 labeled monoclonal antibody in ovarium cancer. J Clin Oncol. 1990;8:1941–1950
  96. Rowlinson-Busza G, Snook D, Epenetos AA. 90Y-labeled antibody uptake by human tumor xenografts and the effect of systemic administration of EDTA. Int J Radiat Oncol Biol Phys. 1994;28(5):1257–1265
  97. DeNardo GL, DeNardo SJ, Kukis DL. Maximum tolerated dose of67Cu-2IT-BAT-Lym-1 for frationated radioimmunotherapy of Non-Hodgkin’s lymphoma: a pilot study. Anticancer Research. 1998;18:2779–2788
  98. Maxon HR, Schroder LE, Thomas SR. Re-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormonal-resistant prostate cancer. Radiology. 1990;176:155–159
  99. Han SH, Zonnenberg BA, de Klerk JMH. 186Re-etidronate in breast cancer patients with metastatic bone pain. J Nucl Med. 1996;40:639–642
  100. Quirijnen JMSP, Han SH, Zonnenberg BA. Efficacy of Rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med. 1996;37:1511–1515
  101. Breitz HB, Weiden PL, Vanderheyden JL. Clinical experience with rhenium-186 labeled monoclonal antibodies for radioimmunotherapy: results of phase 1 trials. J Nucl Med. 1992;33:1099–1112
  102. Griffiths GL, Goldenberg DM, Diril H. Technetium-99 m, Rhenium-186, and Rhenium-188 direct-labeled antibodies. Cancer. 1994;73:761–768
  103. Zhu H, Baxter LT, Jain RK. Potential and linitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med. 1997;38:731–741
  104. Hellman S. Priciples of radiation therapy. In:  Rosenberg SA,  Hellman S,  DeVito V editor. Cancer. 1992;
  105. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiation Oncology. Biol Phys. 1990;18:1261–1269
  106. Zhu H, Jain RK, Baxter T. tumor pretargeting for radioimmunodetection and radioimmunotherapy. J. Nucl Med. 1998;39 (1):65–76
  107. Cremonesi M, Ferrari M, Chinol M. Three-step radioimmunotherapy with yttrium-90-biotin: dosimetry and pharmacokinetics in cancer patients. Eur J Nucl Med. 1999;26:110–120

PII: S0305-7372(99)90146-9

doi: 10.1053/ctrv.1999.0146

Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 3-10 , February 2000

Article Tools